The term Acute-on-Chronic Liver Failure (ACLF) was first introduced in 1995 to describe a condition in which two “lesions” or “insults” act simultaneously on the liver, one of which is chronic and the other is acute. However, the universally accepted and used definition of ACLF is still lacking. Thus, several definitions have been developed by expert groups from the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Asian-Pacific Association for the Study of the Liver (APASL).
Get FREE sample copy at: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
The Acute On Chronic Liver Failure (ACLF) market report also covers emerging drugs, current treatment practices, Acute On Chronic Liver Failure (ACLF) market share of the individual therapies, current and forecasted Acute On Chronic Liver Failure (ACLF) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Acute On Chronic Liver Failure (ACLF) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Acute On Chronic Liver Failure (ACLF) Market Key Facts
-
The total population of Acute-on-Chronic Liver Failure (ACLF) in 7MM was found to be 60,521 in 2017.
-
According to Delveinsight estimates, Germany accounted for the maximum cases which were 17,100 in 2017.
-
Among the 7MM, the United States had the second-highest population of ACLF with 12,577 cases. On the other hand, Italy had the lowest population of 1,721 cases in 2017.
-
Japan accounted for 3,720 cases Acute-on-Chronic Liver Failure (ACLF) in 2017.
Key Benefits of Acute On Chronic Liver Failure (ACLF) Market Report
-
Acute On Chronic Liver Failure (ACLF) market report provides an in-depth analysis of Acute On Chronic Liver Failure (ACLF) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Acute On Chronic Liver Failure (ACLF) market report will help in developing business strategies by understanding the Acute On Chronic Liver Failure (ACLF) Market trends & developments, key players, and future market competition that will shape and drive the Acute On Chronic Liver Failure (ACLF) market in the upcoming years.
-
The Acute On Chronic Liver Failure (ACLF) market report covers Acute On Chronic Liver Failure (ACLF) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Acute On Chronic Liver Failure (ACLF) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Acute On Chronic Liver Failure (ACLF) Market
Acute On Chronic Liver Failure (ACLF) market size is anticipated to increase during the study period owing to the increasing incident population of ACLF patients in the 7MM. The expected launch of new therapies will also fuel the market growth.
The Acute On Chronic Liver Failure (ACLF) market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Acute On Chronic Liver Failure (ACLF) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Acute On Chronic Liver Failure (ACLF) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Acute On Chronic Liver Failure (ACLF) Epidemiology
The Acute On Chronic Liver Failure (ACLF) epidemiology section covers insights about the historical and current Acute On Chronic Liver Failure (ACLF) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Acute On Chronic Liver Failure (ACLF) Epidemiology Segmentation –
-
Cases of Acute-on-chronic liver failure
-
Cases by Grades
-
Organ failures associated with ACLF
-
Potential precipitating events of ACLF
Acute On Chronic Liver Failure (ACLF) Drugs Uptake and Key Market Players
The Acute On Chronic Liver Failure (ACLF) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute On Chronic Liver Failure (ACLF) market or expected to get launched in the market during the study period. The analysis covers Acute On Chronic Liver Failure (ACLF) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamic of the Acute On Chronic Liver Failure (ACLF) market is anticipated to change in the coming years owing to the rise in healthcare spending across the world.
Acute On Chronic Liver Failure (ACLF) Companies:
RHEACELL
Versantis AG
Yaqrit
Grifols Therapeutics
Promethera Biosciences
And many others.
Acute On Chronic Liver Failure (ACLF) Therapies covered in the report include:
PE-A 5%
HepaStem
APZ2
VS-01
Dialive
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Acute On Chronic Liver Failure (ACLF) Competitive Intelligence Analysis
4. Acute On Chronic Liver Failure (ACLF) Market Overview at a Glance
5. Acute On Chronic Liver Failure (ACLF) Disease Background and Overview
6. Acute On Chronic Liver Failure (ACLF) Patient Journey
7. Acute On Chronic Liver Failure (ACLF) Epidemiology and Patient Population
8. Acute On Chronic Liver Failure (ACLF) Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute On Chronic Liver Failure (ACLF) Unmet Needs
10. Key Endpoints of Acute On Chronic Liver Failure (ACLF) Treatment
11. Acute On Chronic Liver Failure (ACLF) Marketed Products
12. Acute On Chronic Liver Failure (ACLF) Emerging Therapies
13. Acute On Chronic Liver Failure (ACLF) Seven Major Market Analysis
14. Attribute Analysis
15. Acute On Chronic Liver Failure (ACLF) Market Outlook (7 major markets)
16. Acute On Chronic Liver Failure (ACLF) Access and Reimbursement Overview
17. KOL Views on the Acute On Chronic Liver Failure (ACLF) Market.
18. Acute On Chronic Liver Failure (ACLF) Market Drivers
19. Acute On Chronic Liver Failure (ACLF) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market
Related Reports –
Acute On Chronic Liver Failure (ACLF) Pipeline Insights
Acute On Chronic Liver Failure (ACLF) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute On Chronic Liver Failure (ACLF) market.
Latest Healthcare Blog –
Antibody-mediated Rejection Market
The rarity of Antibody-mediated Rejection has led to the absence of widely accepted treatment guidelines and FDA-approved therapies in the AMR market. To provide novel therapeutic options, some of the key companies such as CSL Behring, Hansa Biopharma, and Viela Bio are diligently working in the AMR market. To read more about the condition and its future market trends, visit: Antibody-mediated Rejection (AMR) Therapeutics Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/